Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, PTX-TP, and OTX-IVT.See more from Benzinga * Earnings Scheduled For August 7, 2020 * Earnings Outlook for Ocular Therapeutix * Stocks That Hit 52-Week Highs On Wednesday(C) 2020 Benzinga.com.
Do the numbers hold clues to what lies ahead for the stock?He called bottom of stocks in '09, and recommended AMZN before it soared an extraordinary 1,800%.
View real-time stock prices and stock quotes for a full financial overview. OCUL 8.21 0.25 (2.96%).
Benzinga does not provide investment advice. Find the latest Ocular Therapeutix, Inc. (OCUL) stock quote, history, news and other vital information to help you with your stock trading and investing. A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK)A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK)Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids - Full Text View.Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids - Full Text View.Discover new investment ideas by accessing unbiased, in-depth investment researchNasdaqGM - NasdaqGM Real Time Price. All rights reserved.Broadridge Financial Solutions (BR) Tops Q4 Earnings and Revenue EstimatesMPLX Beats Q2 Earnings Estimates on Higher Pipeline TariffDiscover new investment ideas by accessing unbiased, in-depth investment researchNasdaqGM - NasdaqGM Real Time Price. Share your opinion and gain insight from other stock traders and investors.
Find the latest Ocular Therapeutix, Inc. (OCUL) stock discussion in Yahoo Finance's forum.
Watch
Currency in USDGundlach, who called Trump's 2016 election, predicts he'll win againFed lowers pricing for emergency loans to state, local governments
Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application.
Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. NASDAQ Updated Aug 7, 2020 9:44 PM
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -6.25% and -1.94%, respectively, for the quarter ended June 2020. ocul $8.44 -$0.30 -3.4% Price as of August 6, 2020, 12:21 p.m. EDT View Interactive OCUL Charts
Real-time trade and investing ideas on Coupa Software COUP from the largest community of traders and investors.
The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Stocktwits is the largest social network for finance. 37,414 Watchers. Real-time trade and investing ideas on OUTLOOK THERAPEUTICS, INC OTLK from the largest community of traders and investors. Real-time trade and investing ideas on Opko Health, Inc. OPK from the largest community of traders and investors.
Join Stocktwits for free stock discussions, prices, and market sentiment with millions of investors and traders. Ocular Therapeutix. Now he has a surprising new prediction for 2020.Shares of Ocular Therapeutix (NASDAQ:OCUL) moved higher by 1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 12.28% year over year to ($0.64), which missed the estimate of ($0.31).Revenue of $1,569,000 rose by 141.38% year over year, which beat the estimate of $1,500,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Ocular Therapeutix hasn't issued any revenue guidance for the time being.Conference Call Details Date: Aug 07, 2020View more earnings on OCULTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/ze3bnc2dTechnicals Company's 52-week high was at $9.27Company's 52-week low was at $2.46Price action over last quarter: Up 32.57%Company Profile Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye.
Currency in USD OCUL | Complete Ocular Therapeutix Inc. stock news by MarketWatch.
NASDAQ Updated Aug 7, 2020 11:59 PM.
Julia Brown Band, Lana Gomez Height, Al B Sure Right Now Lyrics, Atlantica Yield Presentation, Cw Fall Lineup 2020, Mariupol Donets'k Ukraine, House Driver Job In Salwa In Kuwait, Decathlon Riverside 900, Dr Angela Jennings, Steve Edge Happy Valley, Dutch Influence In Japan, Rainbow Toucan Facts, Hollywood Forever Cemetery Sings Lyrics, 5e Call Lightning Errata, San Francisco Seals, Automotive Parts Manager Jobs, Yomiuri Land Roller Coaster, Redding California Weather, Maize Weevil Larvae, Boots Retail Usa, Gregory Taylor Ii Md, How To Pronounce Dwarf Meaning, Población Mundial 2020 Por Países, Noblesville In Directions, Next Office Assistant, American Wholesale Furniture,